Should I Buy CHRS Stock in 2026?
Data-driven analysis and honest assessment for Coherus Oncology Inc
Current Price: $1.99
Decision Score
Weak
Based on 6 fundamental factors
Score Breakdown:
P/E data not available
Declining -0%
Thin margins (4% net)
Financial health data limited
Negative free cash flow
No recent insider activity
Key Investment Metrics
Current Price
$1.99
P/E Ratio
N/A
Revenue Growth
0.6%
Profit Margin
4.0%
Market Cap
$0.3B
Dividend Yield
None
How CHRS Compares to Competitors
Understanding how CHRS stacks up against peers helps inform your investment decision.
How CHRS Compares to Peers
Upcoming Events for CHRS
+5 Reasons TO Buy CHRS
1. High gross margins of 67%
moderateGross margins above 50% typically indicate strong brand value or intellectual property moats.
-5 Reasons NOT to Buy CHRS
1. Negative free cash flow
high riskBurning cash creates funding risk and limits shareholder returns.
2. Small-cap volatility risk
high riskMarket cap under $2B means higher volatility and lower liquidity.
3. Thin profit margins of 4.0%
medium riskLow margins provide little cushion against cost increases or pricing pressure.
4. Minimal revenue growth
low riskGrowth of 0.6% barely keeps pace with inflation.
Who Should Buy CHRS?
Investment Profile
Risk Level
Very High
Recommended Holding Period
3-5 years
Best For:
Not Suitable For:
- ✗
Growth Investors
Limited 1% growth may disappoint
- ✗
Income-Focused Retirees
No dividend paid
- ✗
Risk-Averse Investors
Very High risk may cause uncomfortable volatility
- ✗
Large Position Traders
Lower liquidity may impact execution
Consider These Alternatives
If you're interested in CHRS, compare these Health Care peers:
Pro tip: Compare CHRS directly with competitors using our comparison tool to see which stock better fits your criteria.
Get the Full Picture
Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for CHRS
Frequently Asked Questions
What is CHRS stock price today?
CHRS (Coherus Oncology Inc) stock is trading at $1.99 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).
Is CHRS stock going up or down today?
CHRS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.
Should I buy CHRS stock now?
The decision to buy CHRS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.
Is CHRS a buy, hold, or sell right now?
Our AI-powered analysis provides buy/hold/sell recommendations for CHRS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.
Is CHRS stock overvalued or undervalued?
Use our DCF valuation calculator to determine if CHRS is overvalued or undervalued based on fundamental analysis and future cash flow projections.
What is CHRS's P/E ratio?
P/E ratio data for CHRS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.
What is CHRS's market cap?
CHRS (Coherus Oncology Inc) has a market capitalization of $0.30 billion, making it a small-cap stock.
What is CHRS's price to book ratio?
CHRS trades at a price-to-book (P/B) ratio of 4.86, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.
Deep Dive Analysis
Explore comprehensive analysis tools to make an informed decision about Coherus Oncology Inc
Full Stock Analysis
Complete CHRS overview with charts and data
Is CHRS Undervalued?
DCF valuation and intrinsic value analysis
Dividend Analysis
Yield, payout ratio, and dividend history
Growth Analysis
Revenue, earnings, and expansion metrics
Financial Health
Debt, liquidity, and balance sheet strength
Price Prediction
2026 forecast and price targets
Stock Forecast
12-month price forecast and analyst targets
Earnings Date
Next earnings date and historical results
Compare Before You Buy
See how CHRS stacks up against its competitors
Similar Investment Decisions
Explore investment analyses for stocks similar to Coherus Oncology Inc
Complete CHRS Analysis
Compare CHRS With
Disclaimer
This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.